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Abstract  
Mutations of the tumor suppressor gene p53 occur in more than 50% of 
human malignancies and lead to the loss of suppressor activity. Moreover 
frequently p53 mutants gain novel, oncogenic properties by transcriptional 
activation of the genes, involved in cellular proliferation, cell survival and 
angiogenesis. Today’s challenge is to understand mechanisms underlying the 
gain-of-function of mutant p53 proteins.  
By the example of KLF4 promoter we demonstrate that mutant p53 can 
carries out its gain-of-function by interaction with another p53 family member, 
transcription factor p63. In the first report we provide strong evidence that KLF4 
is negatively controlled by p63 in normal skin in the presence of physiological 
levels of wild type p53 (wtp53) and that this regulation is subverted by 
oncogenic mutations of p53, establishing a direct link between these TFs, 
commonly overexpressed in squamous cell carcinoma (SCC).  
These results inspired us to investigate the mechanisms of mutant p53 
gain-of-function on the genome scale. In the second manuscript we demonstrate 
that mutant p53 HaCaT alleles are pro-growth and mutp53 have thousands of 
binding sites in the human genome; they affect gene expression profoundly, 
both by binding with p63 to consensus elements and by being tethered by other 
TFs to their locations. 
Although 2 mutant p53 alleles are definitely gain-of-function in the 
HaCaT, they are not sufficient to render these cells malignant. Based on the 
sphere-forming assay we developed novel model for the tumorigenic conversion 
of the HaCaT cells: while immortalized keratinocytes display transformed 
phenotype in vitro and not tumorigenic upon injection into nude mice, HaCaT-
derived spheres give rise to the SCC in vivo. Thus, this simple model can be 
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useful for the future studies of the genetic and phenotypic signatures during 
SCC initiation and development. 
There is an indication that mutant p53 can execute its gain-of-function 
via interaction with NF-Y transcription factor. Ongoing study is devoted to the 
investigation of NF-YA subunit role in the processes of cellular proliferation 
and apoptosis in the cells with different p53 status.  
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State of the Art 
1. The skin 
The smooth surface of the human skin suggests simplicity, but it 
embodies one of the most complex and metabolically active organs, which is 
designed to interact and cope with the environment. The skin is the largest organ 
system of the body which consists of epithelial layer (epidermis), a connective 
tissue layer (dermis) and an adipose layer (hypodermis). As a physical barrier it 
prevents water loss and resists mechanical, chemical and microbial attacks. It 
also functions to regulate temperature, produce hormones and vitamins, such as 
Vitamin D, and responds to environmental factors including ultraviolet 
radiation. 
 
1.1. The keratinocytes and the epidermis 
The outer layer, the epidermis, is a terminally differentiated, stratified 
squamous epithelium that forms protective covering of the skin. The major cell, 
making up 95% of the total, is the keratinocyte, which moves progressively 
from attachment to the epidermal basement membrane towards the skin surface, 
forming several well-defined layers during its transit (Eckert, 1989; Nemes and 
Steinert, 1999).  
Keratinocytes arise from stem cells in the basal layer and progressively 
mature through the spinous and granular layers until they reach the corneal layer  
and are finally shed  into the environment. Thus, in the normal epidermis, there 
is a tightly controlled balance between proliferation and desquamation that 
results in a complete renewal or turnover approximately every 28 days. On its 
journey to the skin surface, the keratinocyte undergoes a complex program of 
terminal differentiation, also called keratinization. This cellular program is 
accompanied by highly regulated and marked changes in gene expression, 
cellular architecture and enzyme activity. Early steps in terminal differentiation 
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of cells arising from the basal keratinocyte result in a permanent loss of growth 
potential, or clonogenicity known as commitment and the subsequent sequential 
expression of differentiation markers. Among the major products of epidermal 
keratinization are the differentiated keratin intermediate filaments which are 
essential for maintaining structural integrity of the epidermis (Fuchs, 1990, 
1993; Fuchs and Byrne, 1994).  
 
1.2. Epidermal growth and differentiation 
Only the basal layer of epidermal cells has the capacity for DNA 
synthesis and mitosis. Under an as yet unidentified trigger of terminal 
differentiation, a basal cell will begin its journey to the skin surface. In transit, it 
undergoes a series of morphological and biochemical changes that culminate in 
the production of dead, flattened, enucleated squames, which are shed from the 
surface, and continually replaced by inner cells differentiating outward. 
The process of epidermal growth and differentiation has been subdivided 
into four parts. Basal cells are distinguished by intracellular cytoskeleton 
composed of a relatively dispersed, but extensive, network of keratin filaments. 
These filaments are made of two distinct keratin proteins: keratin 5 and Keratin 
14 (Nelson and Sun, 1983).  
The four to eight layers of suprabasal spinous cells are postmitotic, but 
metabolically active. These cells devote much of their protein synthesizing 
machinery to manufacturing two new keratins, keratin 1 and keratin 10, forming 
cytoskeletal filaments that aggregate into thin bundles (Eichner et al., 1986). In 
addition, spinous cells make glutamine and lysine-rich envelope proteins, such 
as involucrin, which are deposited on the inner surface of the plasma membrane 
of each cell (Rice and Green, 1979).  
As spinous cells reach the granular layer, they stop generating keratin 
and envelope proteins, and make their final fitting in protein synthesis, including 
production of filaggrin, a histidine-rich basic protein which may be involved in 
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the bundling of single filaments into larger, macrofibrillar cables (Fleckman et 
al., 1985). This process of increased filament packing is thought to enable the 
keratin filaments to be among the few survivors of the massive destructive phase 
which soon occurs. Loricrin, a recently described and major component of the 
cornified envelope is also synthesized at this late stage (Mehrel et al., 1990). As 
each differentiating cell becomes permeable, a calcium inflow activates 
epidermal transglutaminase, which then catalyzes the formation bonds, thereby 
biochemically cross-linking the envelope proteins into a cage (Rice and Green, 
1979). As other lytic enzymes are released, all signs of metabolic activity 
terminate, and the resulting flattened squames are filled with macrofibrils of 
keratin filaments.  
The stratum corneum, composed of terminally differentiated 
keratinocytes sealed together by lipids, is an impermeable, insoluble, and highly 
protective fortress, which keeps microorganisms out and essential bodily fluids 
in. This two compartment system of cellular proteins held together by lipids is 
called the “bricks and mortar”– construct (Nemes and Steinert, 1999). 
 
1.3. Spontaneously immortalized HaCaT keratinocytes 
Fusenig and colleagues established the first and so far unique 
spontaneously immortalized keratinocyte cell line derived from normal adult 
human skin. This cell line was termed HaCaT to indicate that it was developed 
from human adult skin keratinocytes during prolonged cultivation at a reduced 
Ca
2+
 concentration and elevated temperature (Boukamp et al., 1988).  
 
1.3.1. Genetic alterations 
The spontaneous immortalization of the HaCaT cell upon long-term 
cultivation of the normal human adult keratinocytes occurred as a multistep 
process, each stage of which was characterized by a number of genetic changes 
(Boukamp et al., 1988; Boukamp et al., 1997). The first genetic alterations in the 
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HaCaT population detected by means of cytogenetic assay were 3 translocations 
leading to the loss of one copy of chromosome arms 3p, 4p, and 9p as well as 
gain of 9q (Boukamp et al., 1988).  A quantity of senescence genes is located on 
these chromosomes and thus their loss could have contributed considerably to 
the immortalization.  
During continued culture of HaCaT cells additional chromosomal 
changes could be discovered, such a polyploidization (72-88 chromosomes) 
(Boukamp et al., 1988). However, although propagated for more than 300 
population doublings and more than 6 years, HaCaT cells maintained a constant 
balance of genetic material and remained non-tumorigenic in contrast to virally 
transformed keratinocytes (Boukamp et al., 1997). Distinct numerical and 
structural karyotypic alterations during the HaCaT immortalization process are 
present in the Table1 and Fig. 1.  
 
Passage no. Numerical distribuition (% of metaphases) 
Diploid 
(46) 
Hypodiploid 
(38-45) 
Hepotetraploid 
(72-88) 
2 10 90 0 
5 0 67 33 
11 0 58 42 
17 0 0 100 
33 0 0 100 
50 0 0 100 
Table 1. Chromosomal changes of HaCaT cells during adaptation to 
autonomous growth in vitro (Boukamp et al., 1988). 
 
1.3.2. Telomeres and telomerase 
Another mechanism may involve increased activity of the enzyme 
telomerase that was found to be associated with immortalization of HaCaT cells 
(Härle-Bachor and Boukamp, 1996). Telomerase is a specialized cellular 
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enzyme complex with reverse transcriptase activity that maintains stable 
telomere length. In normal cells, continuous shortening of the telomeres occurs 
as cells approach cellular senescence. In contrast, HaCaT cells exhibit 
significantly increased telomerase activity resulting in largely maintained 
telomere length. These observations indicate that telomerase may play an 
important role in the immortalization process of these cells. 
 
Fig. 1. G-banded karyotype of the HaCaT cells at the passage 17 revealed 
hypotetraploidy (mode of 82). 
 
1.3.3. Phenotypic changes in the immortalized HaCaT keratinocytes  
As expected, HaCaT cells displayed increasing growth potential in vitro 
both at high and clonal cell density (Boukamp et al., 1988; Boukamp et al., 
1997). In the soft agar assay HaCaT cells demonstrated anchorage-independent 
growth that was first visible at passage 18 but at a very low frequency and the 
efficiency of the growth in soft agar was always low and remained at maximum 
of 4,5% at high passages. Great increase in the proliferative activity was 
observed upon transition from the passage 37 to the passage 283 HaCaT cells: 
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the population doubling time dropped from 23 to 16 hours (Boukamp et al., 
1997) 
 In immortalized by simian virus 40 T-antigen keratinocytes the loss of 
differentiation was observed, but it’s not the case of the HaCaT keratinocytes: 
even as monolayers, they maintained the capacity to express differentiation 
markers of the epidermis, such as different keratins (Ryle et al., 1989). 
Moreover, HaCaT cell differentiation is still regulated by calcium and as 
differentiation of normal epidermal keratinocytes (Breitkreutz et al., 1993). This 
differentiation capacity is even more obvious when HaCaT cells are grown as 
surface transplants on nude mice (Boukamp et al., 1990; Breitkreutz et al., 1991; 
Breitkreutz et al., 1998).  Under these conditions, HaCaT cells form 
multilayered keratinizing epithelia with a remarkably high degree of 
organization and differentiation.  
Finally, when injected subcutaneously onto nude mice, HaCaT cells do 
not neither give rise to the tumors nor demonstrate invasive growth behavior up 
to the highest passages examined (passage 311) (Boukamp et al., 1997). They 
form epithelial cysts in which cell proliferation stops completely and 
irreversibly within a few weeks (Boukamp et al., 1988). The unique properties 
of HaCaT cells, a permanent and stably non-tumorigenic keratinocyte cell line 
with largely preserved differentiation capacity, made this cell line a paradigm 
for human epidermal keratinocytes used in more than 600 laboratories 
worldwide. 
 
1.3.4. Tumorigenic conversion of the HaCaT cells 
Human cells demonstrate a remarkable resistance to transformation by 
oncogenes and chemical agents, however, once immortalized, human cells can 
be relatively easily transformed into neoplastic cells with these agents (Rhim et 
al., 1990).  
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Human immortalized HaCaT keratinocytes were used as an experimental 
in vitro model for studying the mechanisms of human epidermal multistep 
carcinogenesis (Boukamp et al., 1988; Boukamp et al., 1997; Boukamp et al., 
1990; Fusenig and Boukamp, 1998). Immortalization of a cell is considered an 
early and essential step in the transformation process in vitro (Fusenig and 
Boukamp, 1998). Immortalized cells have morphological alterations, 
chromosome abnormalities, unlimited growth potential - all properties not found 
in any cell of the human body except for cancer cells.  
The oncogenic conversion of the HaCaT cells can be induced by 
introduction of additional genetic alterations, e.g. transfection of the ras 
oncogene (Boukamp et al., 1990), by exposing HaCaT cells to culture stress 
such as growth over many passages in serum-free medium (Hill et al., 1991) and 
propagation of HaCaT cells at elevated temperature (40 ºC) (Fusenig and 
Boukamp, 1998). Furthermore the microenvironment was shown to play a 
significant role in tumorigenic transformation of HaCaT cells. When platelet-
derived growth factor B (PDGF-B) was overexpressed in HaCaT cells grafted to 
mice the cells became tumorigenic (Skobe and Fusenig, 1998). HaCaT cells do 
not express PDGF-receptor and it was concluded that PDGF expressed by 
HaCaT is sufficient to activate stromal cells to produce growth factors which in 
turn stimulate HaCaT proliferation. 
 
1.3.5. Heterogeneity within human epidermal and other cells 
Pioneering work of Barrandon and Green revealed 3 clonal types of 
epidermal keratinocytes with profoundly different proliferative capacity:  
holoclone has the greatest growth potential and forms large rapidly growing 
colonies; fewer than 5% of the colonies abort and terminally differentiate. The 
growth potential of paraclones is limited by 15 generations and then the cells 
abort and terminally differentiate. The meroclone contains a mixture of the cells 
of both types and represent transitional stage between paraclone and holoclone 
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(Barrandon and Green, 1987).  Recent studies demonstrated that clonogenic 
holoclones are bona fide multipotent epidermal stem cells (Barrandon 2005). 
The heterogeneity of the cellular composition was demonstrated not just 
for the normal tissues but also for most human tumors (Heppner et al., 1978). 
Even if the mechanisms underlying the development of tumor heterogeneity still 
remain poorly understood, during the past several years the cancer stem cell 
(CSC) hypothesis for the tumor initiation and progression gained strong support 
in the cancer research community. CSC model assumes that cancers are 
maintained and propagated by a small population of the cells within a tumor that 
possess main stem cell characteristics. The existence of the CSC was first 
demonstrated in the context of human leukemia (Lapidot et al., 1994), but 
recently the CSC subset was identified also in the solid tumors, including 
pancreas (Hermann et al., 2007), prostate (Patrawala et al., 2006), lung (Eramo 
et al., 2008), colon cancer (Ricci-Vitiani et al., 2007).   
Interestingly, also within established malignant cell lines a small 
population of the cells with self-renewal characteristics and ability to give rise to 
the differentiated progeny was found (Kondo et al., 2004; Patrawala et al., 2005; 
Szotek et al., 2006). 
 
2. Tumor suppressor p53 
The p53 tumor suppressor is considered to be one of the most important 
proteins in preventing cancer. The first reports described p53 as protein able to 
interact with SV-40 T antigen (Lane and Crawford, 1979; Linzer et al., 1979). 
The protein was prevalent in many transformed cell lines, unlike normal cells 
where its expression was undetectable (Lane and Crawford, 1979; Rotter et al., 
1980), when ectopically expressed p53 contributed to the cellular transformation 
and there was a great correlation between p53 protein levels and transformation. 
For these reasons ironically p53 was classified initially as protein, associated 
with transformation and proto-oncogene. Luckily Levine and colleagues 10 
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years realized that in all previous reports the mutant forms of p53 were implied 
and their landmark manuscript demonstrated that wild type p53 (wtp53) actually 
inhibits cellular transformation (Finlay et al., 1989).  Thus, wtp53 was 
established as a bona fide tumor suppressor rather than an oncogene.  
Several factors underscore the importance of p53 in tumor suppression: (1) 
p53 is the most frequently mutated gene identified in human cancer (50% of all 
cancers); (2) Li-Fraumeni syndrome is a genetic disease often attributed to a 
germline mutation in p53 (Malkin et al., 1990); people affected by this 
syndrome usually develop malignant tumours by early adulthood, upon mutation 
or deletion of the normal p53 allele; and (3) mice that lack p53 develop 
normally, but are predisposed to developing lymphoma and a broad spectrum of 
other cancers, and usually die from their malignancies within 3–6 months of age 
(Jacks et al., 1994).  
 
2.1.  The p53 gene product 
Human p53 is a 53 kDa nuclear phosphoprotein, encoded by a 20-Kb 
gene containing 11 exons and 10 introns (Lamb and Crawford, 1986).  This gene 
belongs to a highly conserved gene family containing at least two other 
members, p63 and p73, which possess some of the same properties as p53 
(Prives and Hall, 1999). 
wtp53 protein is composed of 393 amino acids and is commonly 
divided into three functional domains (Fig. 2):  the N-terminus contains an 
acidic domain (amino acids 1–42) that interacts with components of the 
transcriptional machinery, such as TBP and TAFs and a proline-rich region with 
multiple copies of the PXXP sequence (residues 61-94, where P is proline and X 
- any amino acid). Acidic domain was demonstrated to be crucial for the p53 
transcriptional activity (Lu and Levine, 1995) and proline-rich domain is 
required for apoptosis (Walker and Levine, 1996) and is involved in the p53 
negative regulation: this region region plays a role in p53 stability regulated by 
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MDM2, wherein p53 becomes more susceptible to degradation by MDM2 if this 
region is deleted (Sakamuro et al., 1997). The central core domain (AA 102-
292) contains domain for specific DNA binding and recognizes at least two 
repeats of the DNA consensus sequence 50-PuPuPuC(A/T)-(T/A)GPyPyPy-30 
(Levine, 1997). The oligomerization domain of wtp53 (AA 324–355) 
participates in the formation of p53 tetramers (dimers of dimers) and this form 
typically binds DNA in a sequence-specific manner (Wang et al., 1993). The C-
terminus of p53 (AA 311–393) includes a nuclear localization sequence and 
exhibits nonspecific DNA binding (Wu et al., 1995). The role of these 
interactions is still not well understood. The C-terminus also functions as a 
negative regulatory domain, perhaps in coupling with DNA-binding domain, to 
maintain p53 in an inactive form till posttranslational modifications don’t active 
the protein.  
 
Figure 2. p53 protein structure. The 53 kDa nuclear phosphoprotein p53, of 393 amino 
acids, comprises several domains, including an acidic N-terminal region containing the 
transactivation domain, a core containing the sequence-specific DNA-binding domain 
and a complex C-terminal domain with multiple functions (Bode and Dong, 2004). 
 
2.2. The physiological functions of p53 
p53 protein is a tumor suppressor and transcription factor, that plays 
central role in prevention of the inappropriate cell growth and maintenance of 
the genome integrity following genotoxic stress (Vogelstein et al., 2000; 
Vousden and Lu, 2002). After DNA damage (ionizing radiation, UV radiation, 
cytotoxic drugs treatment, viral infection), heat shock, hypoxia, and oncogene 
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overexpression, p53 protein undergo post-translational modifications, this leads 
to overall increase of protein level and as a consequence to the p53 activation 
(Vogelstein et al., 2000; Vousden and Lu, 2002).  The ability of p53 to execute a 
role of tumor suppressor is attributed to its ability to act as sequence-specific 
transcription factor that regulates expression of numerous genes (Farmer et al., 
1992). Genes activated by wtp53 are functionally diverse and belong to different 
signalling pathways such as cell-cycle checkpoints, cell survival, apoptosis, and 
senescence (Hofseth et al., 2004). 
Activation of p53 primarily results in cell cycle arrest, presumably to 
allow for DNA repair before replication or mitosis. A mechanism by which p53 
blocks cell cycle progression is through the transcriptional activation of 
p21
WAF1/CIP1
 (Prives and Hall, 1999). In normal cells p21 inhibits cyclin-
dependent kinases, thereby preventing phosphorylation (inactivation) of Rb, 
which consequently arrests cells in the G1/S phase. Gadd45a is also induced by 
p53 in response to DNA damage (Kastan et al., 1992). The Gadd45 gene 
product interacts with various cell cycle-related proteins such as Cdc2 and 
PCNA and contributes to DNA repair and G2/M cell cycle arrest (Smith et al., 
1994). Gadd45a-deficient mice display increased genomic instability and 
radiation-induced carcinogenesis, similar to p53-deficient mice (Hollander et al., 
1999). Thus, Gadd45 participates together with p53 in maintenance of genomic 
stability. 
In some cell types, activation of p53 results in apoptosis rather than cell 
cycle arrest. Activation of the cell death program by p53 is not clear, but a 
number p53 target genes are well established pro-apoptotic inducers. One such 
gene is bax, and overexpression of Bax protein is sufficient to induce cell death 
(Miyashita and Reed, 1995).  The insulin-like growth factor binding protein 3 
(IGF-BP3) is also regulated by p53 and IGF-BP3 may activate apoptosis by 
selectively blocking mitogen-activated survival signalling pathways (Levine, 
1997). Other p53-regulated genes that may contribute to apoptosis include 
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KILLER/DR5 and FAS/APO1 (both membrane receptors in the TNFR 
superfamily) (Owen-Schaub et al., 1995) and Noxa, ei24/PIG8 and Puma (Yu et 
al., 2001).  
It’s well known that wtp53 is also able to repress a number of cellular 
promoters. For example, expression of the survival factor Bcl-2 is suppressed by 
wtp53 (Miyashita et al., 1994) and loss of this regulation by p53 mutation or 
inactivation may lead to an up-regulation of Bcl-2 expression and an impaired 
apoptotic response to genotoxic damage. Expression of the c-myc proto-
oncogene is also repressed by wtp53 (Moberg et al., 1992) and elevated levels of 
c-Myc promote cell cycle progression (Baudino and Cleveland, 2001). As a 
result, impaired regulation of c-Myc expression through p53 mutation may lead 
to improper signalling and cell growth, thereby contributing to tumor formation. 
Thus, p53-mediated transcriptional repression represents another important 
biological activity, apart from transactivation, by which p53 can negatively 
regulate cell growth. 
 
2.3.  Transcription factor p63 
Transcription factor p63 is a member of p53 family that plays a central 
role in the development of stratified epithelium such as epidermis, breast and 
prostate. p63 expresses multiple protein isoforms: p63 can be expressed from 
two different promoters that gives rise to TA- and ΔNp63 isoforms. p63 exhibits 
60% homology with p53 in DNA-binding domain and it is 37% identical to p53 
in the oligomerization domain (Barbieri et al., 2006). At the C-terminus of p63 
α, β, γ isoforms can be produced creating another level of p63 protein diversity. 
α isoform possess a Sterile alpha-motif (SAM) that is involved in protein-
protein interactions (Schultz et al., 1997). TAp63 isoforms could transactivate a 
reporter gene through a canonical p53 responsive element as well as induce 
apoptosis (Osada et al., 1998; Yang et al., 1998). Tap63α is the most potent 
transactivator of the p63 isoforms (Yang et al., 1998). On the contrary, ΔNp63 
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displays dominant-negative effect on the p53-mediated transcriptional activation 
(Yang et al., 1998). ΔNp63 is expressed in the proliferative, basal compartment 
of epithelia, and it’s specifically expressed in epidermal stem cells that possess 
the highest proliferative potential (Westfall et al., 2003). Numerous studies have 
shown that ΔNp63α is predominant, if not the only one isoform, expressed in 
epithelial cells (Mills et al., 1999; Yang et al., 1999). ΔNp63α isoform is 
overexpressed in several epithelial cancers and was detected to have oncogenic 
potential (Hibi et al., 2000).  
p63 deficient mice demonstrate severe developmental problems, for 
example, the lack of stratified squamous epithelia (Mills et al., 1999; Yang et 
al., 1999). In the absence of epidermal barrier the mice dehydrate and die shortly 
after birth. In addition p63-/- mice have major defects in limb development 
(Osada et al., 1998; Yang et al., 1998). Mutations of p63 in humans also results 
in numerous developmental defects: malformation of hands and feet, epidermal 
dysplasia (EEC syndrome) (Roelfsema and Cobben, 1996).  
 
2.4.  Mutations of p53 
Mutations in the p53 gene are the most frequent mutations observed in 
human cancers (Hollstein et al., 1991). The unique feature of p53 compared to 
other tumor suppressor genes is its mode of inactivation: while most tumor 
suppressor genes are inactivated by mutations leading to absence of protein 
synthesis (or production of a truncated product), more than 80% of p53 
alterations are missense mutations that lead to the synthesis of a stable full-
length protein (Soussi and Béroud, 2001) (Fig.3). This selection is believed to be 
necessary for both a dominant negative activity on wtp53 in the heterozygous 
cells, and for a gain-of-function that transforms mutant p53 into a dominant 
oncogene.  
 An important feature of the p53 protein is the extreme fragility of the 
DNA binding domain (residues 90–300) (Milner, 1995), as more than 200 of the 
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393 residues have been found to be modified. Most p53 mutations are localized 
in the DNA binding domain of the protein (residues 100–300) with 80% of p53 
mutations located on exons 5–8 (residues 126–306) (Soussi and Béroud, 2001). 
Of the mutations in this domain, about 30% fall within 6 “hotspot” residues 
(residues R175, G245, R248, R249, R273, and R282) and are frequent in almost 
all types of cancer (Cho et al., 1994). Codon distribution of p53 mutations is 
represented in the Fig.4.  
 
Figure 3. Distribution of p53 mutation type. Somatic mutations – mutations effect 
(N=28581) (Petitjean et al., 2007). FS –frameshift mutation.  
 
All p53 mutations can be divided into 2 classes on basis of p53 
structural differences: mutations that change p53 folding and mutations in the 
residues involved in DNA recognition (Gannon et al., 1990). Class I mutations, 
exemplified by mutants at codon 248 (7.6% in the p53 database, 
http://p53.free.fr/), affect amino acids directly involved in the protein–DNA 
interaction (Cho et al., 1994). They have a wild-type conformation and they do 
not bind to the chaperone hsp70 (Ory et al., 1994). Class II mutations, 
exemplified by the R175H mutant (4.9% in the database), have an altered  
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Figure 4.  Codon distribution of TP53 mutations (Petitjean et al., 2007). 
 
conformation with intense binding to hsp70. These mutations are associated 
with a more severe phenotype in vitro than class I mutations (Ory et al., 1994). 
Such heterogeneity can also lie in the nature of the resulting residue. Mutant 
R273H has a wild type conformation whereas mutant R273P is denatured (Ory 
et al., 1994). 
 
2.5. Biological effect of mutation 
The concept that mutant p53 acquires some novel, tumor-promoting 
properties, was established more than 2 decades ago (Dittmer et al., 1993; Sigal 
and Rotter, 2000). Several studies on genetically modified mice, harbouring 
some of the most frequently observed in cancers p53 mutations  provide a strong 
evidence of mutant p53 gain-of-function: in contrast to p53 heterozygous or null 
mice (p53
+/-
 
 
or p53
-/-
) mice with one p53 allele mutated developed diverse 
tumor spectrum – in addition to lymphomas more carcinomas and sarcomas 
were observed. The following tumours demonstrated enhanced resistance to 
chemotherapy and genomic instability (Lang et al., 2004; Olive et al., 2004). In 
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cell culture models mutant p53 was proved to participate in different pathways: 
mutant p53 was able to promote invasion, migration, angiogenesis, proliferation 
and survival.  
Different models have been proposed to explain the contribution of 
mutant p53 to tumor progression (Fig.5): 1) loss of wtp53 tumor suppressor 
activity; 2) dominant-negative inhibition of wtp53 function, and possibly p53 
family members (p73/p63), through oligomerization with mutant p53 in 
heterozygous cells; and 3) gain-of-function which confers a selective growth 
advantage to cells expressing mutant p53. 
 
2.6. Dominant-negative interference with p53 family members 
One of the hypotheses to explain mutant p53 pro-oncogenic activity 
assumes that some mutant p53 proteins can interact with and downregulate the 
transcriptionally active forms of p53 homologous, p63 and p73, leading to 
reduced apoptotic response and chemioresistance in tumor cells. 
p63 and p73 genes are members of p53 family that share significant 
homology and whose products can function as sequence-specific transcriptional 
activators (Jost et al., 1997; Kaghad et al., 1997; Osada et al., 1998). It has been 
demonstrated that ectopic expression of p73 and p63 can transactivate 
endogenous targets of p53, such as the cell cycle inhibitor p21 (Jost et al., 1997; 
Kaghad et al., 1997; Pinhasi-Kimhi et al., 1986), as well as p21-containing 
promoters (Jost et al., 1997; Pinhasi-Kimhi et al., 1986; Yang et al., 1998). Di 
Como et al. have shown that p73 can activate other p53 target promoters (Di 
Como et al., 1999) such as the proapoptotic bax gene (Miyashita and Reed, 
1995), IGF-BP3 (Buckbinder et al., 1995) and cyclin G (Okamoto and Prives, 
1999). 
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Figure 5. Proposed mechanisms for the role of p53 mutations in tumorigenesis. 
(A) Loss-of-function. The wtp53 tetramer (green) is transcriptionally active in response 
to cellular stresses and induces the expression of downstream target genes, such as 
p21
Cip1
. An inactivating mutation (purple) or deletion of p53 (purple dotted line) results 
in a complete loss-of-function that eliminates the p53-mediated stress response. (B) 
Dominant-negative. Some p53 mutants (orange) oligomerize with wtp53 (green) (C) 
Gain-of-function. Other p53 mutants (fuchsia) possess new functions not shared by 
wtp53. These are referred to as gain-of-function mutants, which do not transactivate 
normal p53 target genes; rather, these mutants transactivate a different subset of genes, 
such as MDR1 and c-myc (Cadwell and Zambetti, 2001). 
 
One of the cellular functions of p53 is to induce apoptosis in response to 
genotoxic stress, such as damaged DNA (Gottlieb and Oren, 1996; Ko and 
Prives, 1996; Levine, 1997). Similarly, it has been found that overexpression of 
both p73 and p63 can inhibit cell growth by inducing apoptosis (Jost et al., 
1997; Osada et al., 1998; Zhu et al., 1998). 
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Despite the reports mentioned above the role of p63 and p73 in tumor 
suppression is still unclear. p63 and p73 knockout mice display defects in 
development rather than increased tumorigenesis: transgenic p73
-/-  
mice harbour 
developmental problems in their nervous and immune systems (Yang et al., 
2000) and p63
-/-
 mice present severe defects in limb and skin development 
(Yang et al., 1999). Furthermore, p63/p73 mutations are not commonly found in 
human tumours: only 3 missense p73 mutations have been found among almost 
1000 tumours screened. Multiple studies demonstrate that in different tumour 
types there is an overexpression of p73 (Kovalev et al., 1998; Sunahara et al., 
1998; Yokomizo et al., 1999; Zaika et al., 1999). More recently the 
overexpression has been shown also for ΔNp63 isoform (Crook et al., 2000; 
Park et al., 2000; Yamaguchi et al., 2000). Moreover endogenous p73 can be 
stabilized upon treatment with DNA-damaging agents and its inactivation results 
in enhanced chemoresistence (Bergamaschi et al., 2003; Irwin et al., 2003). 
Although less studied, endogenous p63 can determine chemotherapeutic 
efficiency (Gressner et al., 2005). Finally, in one genetic background mice 
heterozygous for p63 and p73 can develop tumours (Flores et al., 2005).  
It has been shown that a number of p53 mutants are able to associate 
with p73 and p63 in co-immunoprecipitation assays when they are either 
expressed ectopically or endogenously (Bergamaschi et al., 2003; Di Como et 
al., 1999; Gaiddon et al., 2001; Irwin et al., 2003; Marin et al., 2000; Strano et 
al., 2000). Both “conformation” mutants (e.g. R175 and G245) and “contact” 
p53 mutants (e.g. R248, R273, R283) have been reported to associate with 
p63/p73. Furthermore, purified mutant p53 and p63/p73 can bind to each other, 
strongly indicating that this interaction is direct (Gaiddon et al., 2001; Strano et 
al., 2002).  
Even if the structural basis of interaction between mutant p53 and its 
homologues is still not well understood, there is a strong evidence that p53 
mutants can decrease transcriptional activity of p73 and p63 and their ability to 
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induce growth suppression and apoptosis (Bergamaschi et al., 2003; Di Como et 
al., 1999; Gaiddon et al., 2001; Marin et al., 2000; Strano et al., 2000). 
Importantly, these studies indicate good correlation between mutant p53 binding 
efficiency and inactivation of p73/p63. Since mutant p53 interacts with p73/p63 
DNA-binding domain (Strano et al., 2002), it’s possible that p73 and p63 are no 
longer able   to recognize and bind its target genes. Moreover it has been 
demonstrated in ChiP experiments that p63 recruitment to the target genes as 
p21, bax was impaired in the presence of endogenous or ectopic mutant p53 
(Strano et al., 2002).  
Taking into account all these studies we can put forward a hypothesis 
that mutant p53 can contribute to the cellular chemoresistance by inhibiting 
endogenous p73 and p63 (Bergamaschi et al., 2003; Irwin et al., 2003). 
Particularly, human tumours that express endogenously or ectopically mutant 
forms of p53 capable to bind p73 are more resistant to chemotherapy. It’s worth 
mentioning that cells harbouring p53 mutants that have a greater potential to 
bind p73 are more resistant to chemotherapeutic drugs. Mutually, 
downregulation of mutant p53 by introduction of small-interfering RNA 
enhances the cellular response to drug-induced cell death.  
In summary, results obtained from cell culture, mouse models and 
clinical correlation have implied that some mutants of p53 have gained novel 
function by inactivation of p63/p73.  
 
2.7.  Mechanisms of mutant p53 gain-of-function 
Several models have been proposed to explain mutant p53 gain-of-
function: 1) altered DNA binding by mutant p53; 2, 3) changes in interaction of 
mutant p53 with other protein, for example, transcriptional factors; 4) or with 
proteins that are not directly involved in the regulation of gene expression.  
As it was mentioned above most p53 mutants possess amino acid 
substitution in the DNA-binding domain and don’t affect N-terminal 
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transactivation domain. From this point of view it’s reasonable to contemplate 
that mutation in the DNA-binding domain would rather attenuate than eliminate 
completely DNA binding. It’s apparent that mutant p53 still possesses DNA 
binding activity even if the ability to recognize classical wtp53 response 
elements is impaired (Ludwig et al., 1996; Thukral et al., 1995). The presence of 
mutant p53 bound to DNA allows to put forward a hypothesis that mutant p53 
can recognize unique mutant p53 responsive element, which allows it to 
function as oncogenic factor (Strano et al., 2007; Weisz et al.). However, a 
consensus for mutant p53 binding still hasn’t been recognized (Donzelli et al., 
2008; Vaughan et al., 2012).  
Another transcriptional activity of mutant p53 consists in interaction with 
other transcription factors that leads to altered regulation of the target genes 
(Bargonetti et al., 1997; Sampath et al., 2001; Stambolsky et al., 2010). In some 
cases, mutant p53 can enhance the transcription by forming complex with 
transcriptional partner factor, cofactors and other proteins. In other cases the 
picture can be more complex, for example, in the case of interaction with NF-Y 
mutant p53 is recruited to its transcription regulatory complex in response to 
DNA damage and it deregulates the cell cycle checkpoint (Fig. 2b) (Di Agostino 
et al., 2006; Liu et al., 2011). In the same way following genotoxic stress DNA 
topoisomerase 2-binding protein 1 (TopBP1) interacts with p53 mutants and 
NF-YA and promotes mutant p53 and p300 recruitment to NF-Y target gene 
promoters with following activation of the NF-Y target genes activation (Liu et 
al., 2011).  
On the other hand the interaction with mutant p53 can be inhibitory. 
Involvement of p53 family members as p63 and p73 – is one of the best 
examples confirming this model (Gaiddon et al., 2001; Strano et al., 2002). 
Several reports demonstrated that mutant p53 binds to p63 and p73 and restrains 
its binding to DNA (Girardini et al., 2011; Liu et al., 2011). In our recent work 
we provide a proof that mutant p53 is actually hijacked to DNA by p63 and 
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albeit p63 binding at the classical p63 responsive elements to some other sites, 
consequently changing the regulation of its target genes expression (Martynova 
et al., 2012). The main obstacle to get inside mutant p53 and p63/p73 interaction 
is an existence of various, functionally diverse isoforms of p53 family members: 
TA isoforms of p63 and p73 (containing the full-length sequence) and the ΔN 
forms (lacking the N-terminus). All these isoforms are transcriptionally active, 
but each regulates a different group of genes. Intriguingly, although mutant p53 
inhibits the transcriptional activity of the TA isoforms, in some systems the 
mutant p53–p63 interaction was found to enhance — rather than repress — the 
expression of some p63-regulated genes (Neilsen et al., 2011). This may reflect 
a different effect of mutant p53 on TA and ΔNp63, and indicates that, as is also 
the case for vitamin D receptor (VDR) and the SP1 transcription factor, mutant 
p53 might act as both an activator and repressor of p63 function (Bargonetti et 
al., 1997; Gualberto and Baldwin, 1995; Stambolsky et al., 2010).  
Another “dark side” of mutant p53 is that it also binds and modulates the 
function of proteins that are not directly involved in transcription. For instance, 
p53 gain-of-function mutants promote tumorigenesis by a novel mechanism 
involving active disruption of critical DNA damage-response pathways: p53 
mutants interact with the nuclease Mre11 and suppress the binding of the 
Mre11-Rad50-NBS1 complex to DNA double-stranded breaks, leading to 
impaired ATM activation and as consequence, impaired homologous 
recombination (Liu et al., 2010; Song et al., 2007). Furthermore, the structural 
mutant p53 proteins interact with BTG2, a cell cycle regulator, preventing it 
from de-activating H-Ras — with the potential for a number of oncogenic 
outcomes (Solomon et al., 2012). 
It has been also demonstrated that mutant p53 gain-of-function can also 
contribute to genomic instability and this effect is mediated by topoisomerase 1 
(Top1), which maintains topology of DNA. Whereas wtp53 both promotes and 
counteracts Top1 function, mutant p53 has specifically lost the negative 
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regulation of Top1, resulting in hyper-recombination and genomic instability 
(Restle et al., 2008).  
 Since mutant p53 is expressed at high levels in human tumors it makes 
this protein extremely attractive target for the anticancer drug development. 
Ongoing studies are focused on destabilization or inactivation of mutant p53, 
restoration of wtp53 functions of the mutants or inhibition of mutant p53 
aggregation with other proteins. Several molecules have been already unraveled 
and they are promising for the clinical application in the future. The main 
obstacle to develop anticancer agents targeting mutant p53 is that different p53 
mutants are not functionally identical and therapy should be designed based on 
the type of p53 mutation present in the cancer. This problem represents a 
challenge for investigators and opens a wide field for the future research work.  
 
2.8. UV-induced p53 mutations in HaCaT cells 
The p53 gene is mutated in a large number of tumors, including 
squamous cell carcinomas and basal cell carcinomas of the skin (Brash et al., 
1991; Brash et al., 1996). Interestingly, in skin carcinomas and also in 
premalignant lesions on sun-exposed sites, the p53 mutations are mostly C to T 
base transitions, including about 10% CC → TT double base changes, which are 
characteristic consequences of UV-induced pyrimidine dimers in DNA 
(Nakazawa et al., 1994). This is in accordance with epidemiologic data that 
clearly demonstrated that UV is one of the most important carcinogenic agents 
for inducing skin tumors. Mutations in the p53 gene are considered early if not 
initial events in the development of skin cancer (Ziegler et al., 1994). 
In accordance with the data obtained from skin carcinomas, HaCaT cells 
exhibited mutations in both alleles of the p53 gene, as do a number of skin 
carcinomas (Brash et al., 1996). Interestingly, the p53 mutations in the HaCaT 
cell line were identified as a C → T transition at codon 179 and a CC → TT 
base change at codons 281 and 282 (Lehman et al., 1993). Because these 
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changes are in typical UV hot spots (Brash et al., 1996) and the biopsy sample 
from which the primary keratinocyte cultures were obtained was from a sun-
exposed area, these p53 mutations probably occurred in the patient and 
subsequently caused the immortalization of the HaCaT cells. However, the 
mutations in the p53 gene might not have been solely responsible for the 
immortalization of HaCaT cells, because so far transfection of mutant p53 into 
human keratinocytes has failed to induce immortality. Hence, other genetic 
changes leading to the loss of senescence genes may be required for completion 
of this process. As mentioned above, the immortalized phenotype developed 
during prolonged cultivation of the keratinocytes in primary culture, and this 
cultivation was initially performed at an elevated temperature of 38.5°C. Higher 
culture temperatures induce increased rates of chromosomal breaks and 
translocations as well as a higher proliferative activity in keratinocytes and 
fibroblasts (Boukamp et al., 1988; Marczynska et al., 1980). Thus, elevated 
temperatures may also have contributed to an increased rate of genetic 
alterations during the process of HaCaT cell immortalization. 
In view of these findings, it can be hypothesized that the UV-induced 
p53 mutations in situ, in combination with stressful culture conditions that led to 
increased genetic alterations, caused the immortalization of the HaCaT cells. In 
skin cancer in humans, UV-induced p53 mutations are probably an initial event 
caused by excessive UV irradiation. This, however, is usually combined with 
sunburn, which increases skin temperature, which may in turn increase the 
number of genetic alterations. The postulated etiology of HaCaT cells may thus 
be representative for the early mechanism of skin carcinoma induction. From 
these data and the considerations outlined above, it can be concluded that the 
HaCaT cell line is indeed a biologically meaningful in vitro model for studying 
human skin carcinogenesis. 
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3. Nuclear Factor Y (NF-Y) 
The CCAAT box is one of the most common cis elements present in 30% 
of all eukaryotic promoters (Bucher, 1990). A number of CCAAT-binding 
proteins have been identified and nuclear factor for Y box (NF-Y) is the most 
ubiquitous and specific acting as a key proximal promoter factor in the 
transcriptional regulation of different eukaryotic genes. For NF-Y binding all 5 
nucleotides are and there is a strong preference for specific flanking sequences. 
Genes that harbor NF-Y sites include constitutive, inducible, and cell-cycle-
dependent genes, but the mechanism of regulating the expression of these 
different genes cannot simply be due to NF-Y DNA binding. It is likely that 
additional factors will be involved in the action of NF-Y. Indeed, recent studies 
from several laboratories have suggested that NF-Y interacts, either functionally 
or physically, with other transcription factors or nuclear proteins both in vitro 
and in vivo (Framson and Bornstein, 1993; van Ginkel et al., 1997; Zwicker et 
al., 1995). 
NF-Y is a heteromeric protein composed of three subunits, NF-YA, NF-
YB and NF-YC, all indispensable for DNA binding (Sinha et al., 1995). Each of 
the three subunits possesses highly conserved domains. Association of NF-YB 
with NF-YC is necessary for NF-YA binding and sequence-specific DNA 
interactions (Sinha et al., 1995). Both NF-YB and NF-YC conserved domains 
contain putative histone fold motifs (Baxevanis et al., 1995). This motif, 
common to all core histones, enables histones to dimerize with companion 
subunits; this motif is responsible for formation of the histone octamer. Recent 
experiments indicate that this 65 amino acid long motif is necessary for subunit 
interactions and DNA binding (Sinha et al., 1996).  
NF-Y was initially identified as the factor associating with the so-called 
Y-box, a conserved element of major histocompatibility complex class II 
promoters (Dorn et al., 1987; Hooft van Huijsduijnen et al., 1990). This 
transcription factor is involved in the activation of numerous other eukaryotic 
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promoters such as the type I collagen, albumin, globin, thrombospondin 1, and 
human thymidine kinase gene promoters (Chodosh et al., 1988; Delvoye et al., 
1993; Framson and Bornstein, 1993; Mantovani et al., 1992; Raymondjean et 
al., 1988). NF-Y is specifically required for genes regulated during the cell-
cycle and inducible by external stimuli: essentially all G2/M genes, for example, 
are dependent on NF-Y (Elkon et al., 2003; Hu et al., 2006). NF-Y is generally 
important to recruit neighbouring TFs and, in some systems, PolII, before 
induction of transcription (Kabe et al., 2005). Consistent with the widespread 
activity, inactivation of the NF-YA gene in mice is embryonic lethal at a very 
early stage of development (Bhattacharya et al., 2003). 
 
3.1.  Role of NF-Y in cellular proliferation and apoptosis 
The NF-YA isoform of the NF-Y transcription factor is believed to be 
the limiting and regulatory subunit of the trimer, tightly regulated by post-
translational modifications (Dolfini et al., 2012a). Expression of the protein is 
modulated during the cell cycle (Bolognese et al., 1999) and its inactivation 
leads to downregulation of the cell-cycle genes in differentiated muscle cells 
(Farina et al., 1999; Gurtner et al., 2003). Moreover NF-Y was shown to be a 
crucial TF, required for moues ES cell proliferation (Grskovic et al., 2007).  
Previous studies aimed at understanding the biological role of NF-Y took 
advantage of a loss of function approach, such as expression of dominant-
negative NF-YA mutants and conditional deletion of the mouse NF-YA gene. 
When a dominant-negative NF-YA mutant that interacts with -YB/YC but does 
not bind DNA is expressed in mouse fibroblasts, retardation of cell growth is 
observed {Hu, 2000}. In MEFs conditional inactivation of NF-YA results in a 
block in cell proliferation and inhibition of S phase or DNA synthesis, which is 
followed by induction of apoptosis  (Bhattacharya et al., 2003). Taken together, 
these studies demonstrate that binding of NF-Y to cellular promoters is essential 
for cell proliferation. 
 
 
29 
 
Apoptosis and proliferation are intimately connected. A tight association 
between regulation of cell cycle and apoptosis was demonstrated for c-myc, 
E2F1, and cyclins. These genes may induce cell proliferation, cell-cycle arrest, 
or cell death, with the different outcomes depending on cell type, cellular 
environment, and genetic background (Vermeulen et al., 2003). Intriguingly, 
many of these genes are NF-Y transcriptional targets (Di Agostino et al., 2006; 
Elkon et al., 2003; Farina et al., 1999; Manni et al., 2001).  
Less is known by the moment about involvement of NF-Y in the process 
of programmed cell death. Hughes et al. demonstrated that NF-Y actively 
participates in the regulation of the Bim expression that is well known mediator 
of apoptosis in many cell types. Their results indicate that NF-Y cooperates with 
FOXO3a to recruit CBP/p300 to the Bim promoter to form a stable multi-
protein/DNA complex that activates Bim transcription after survival factor 
withdrawal (Hughes et al., 2011).  
Furthermore, it was demonstrated that NF-Y interacts with endogenous 
Fas/APO1 promoter and these cooperation is enhanced upon DNA damage 
(Morachis et al., 2010). Moreover overexpression of the NF-Y complex can 
stimulate basal Fas/APO1 transcription in vivo. Thus, NF-Y positively regulates 
Fas/APO1 expression.  
 Several studies implicated a relationship between p53 and NF-Y in 
which p53 interacts directly with NF-Y to repress various cell cycle genes 
(Imbriano et al., 2005). Interestingly, Morachis et al. provide a proof that NF-Y 
knockdown by siRNA causes apoptosis while activating many p53 target genes 
(Morachis et al., 2010). They analyzed RNA levels in NF-Y knockdown cells 
and observed activation of Fas/APO1, p21, and PUMA genes. This is consistent 
with previous studies (Benatti et al., 2008).  
Recent reports underline a role of NF-YA subunit in the processes of 
apoptosis, although a role of this protein the programmed cell death is not well 
understood yet.  Numerous efforts to study the role of NF-YA in the cellular 
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proliferation and apoptosis by overexpression experiments were non successful 
neither in our lab nor in other research groups. Gurtner et al. failed to obtain 
stable clones overexpressing NF-YA, since in MEFs unrestrained NF-Y activity 
promotes apoptosis depending on E2F1 induction and wtp53 activation. On the 
other hand also inactivation of the NF-YA leads to a remarkable apoptotic 
response (Benatti et al., 2011).  
 
3.2. Different NF-YA isoforms 
Due to alternative splicing event subunit NF-YA exists in human and 
mouse cells in short (NF-YAs) and long (NF-YAl) isoforms (Li et al., 1992a; Li 
et al., 1992b). The long isoform carries the full complement of the gene 
sequence. In short isoform 84 nucleotides are missing; the reading frame is 
maintained, so that the protein encoded by “short form” mRNAs is shorter by 28 
amino acids. Expression of different NF-YA isoforms was demonstrated to be 
tissue-specific: the long form is more prevalent in the brain, liver, lung, and in 
fibroblast and teratocarcinoma cells. Conversely, the short form predominates in 
thymus and spleen and in cells of the B lymphoid lineage (Li et al., 1992a).  
Nowadays there is a growing body of evidence about functional duality 
of NF-YA isoforms: the first indication that NF-YA isoforms are functionally 
diverse comes from the study of Cystathionine-β-synthase promoter (Ge et al., 
2002). NF-YAs demonstrated significantly less synergistic transactivation of the 
CBS-1b promoter with Sp1 than NF-YAl. Another report provides strong 
evidence that NF-YAs is a potent cellular regulator of mouse hematopoietic 
stem cell self-renewal (Dolfini et al., 2012a). Report of our laboratory describes 
NF-YAs as a crucial TF, involved in the processes of mouse embryonic stem 
cell (ESC) renewal: NF-YA was demonstrated to activate directly key stem cells 
genes and, and to promote in the indirect way the association of NANOG to a 
large part of its regulated ESCs targets (Dolfini et al., 2012b). 
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4.3. NF-Y and mutant p53 interaction 
Even if the mechanisms of mutp53 gain-of-function are still not yet well 
defined, several models have been arisen. The model of direct transcriptional 
regulation proposes that mutant p53 proteins, most of which are not supposed to 
bind DNA directly, may selectively regulate the expression of downstream 
targets by interacting with other factors that tether p53 to the 
promoter/regulatory regions of these genes. Di Agostino et al. provide strong 
experimental support for this model (Di Agostino et al., 2006).  The authors 
demonstrate that three different mutant p53 (p53His175, p53His273, 
p53His273/Ser309) interact physically with the heterotrimeric transcription 
factor NF-Y in vivo and these mutant p53/NF-Y complexes modulate the 
expression of key NF-Y-regulated cell cycle genes after adriamycin treatment. It 
has been already reported that upon DNA damage the expression of some cycle-
related NF-Y targets is repressed by wtp53: wtp53 forms a complex with NF-Y 
on CCAAT box-containing promoters, and upon DNA damage this complex 
recruits histone deacetylases (HDACs) and releases histone acetyltransferases 
(HATs), coinciding with the repression of key cell cycle (Imbriano et al., 2005; 
Manni et al., 2001).  Strikingly, Di Agostino et al. show that mutant p53/NF-Y 
complexes have the opposite effect on transcription to wtp53/NF-Y complexes: 
at the transcriptional level the expression of NF-Y target genes, involved in cell 
cycle control (cyclin A, cyclin B1, cyclin B2, cdk1, cdc2). 
Mutant p53/NF-Y/HDAC1 complexes were found in the promoters of 
NF-Y target genes and the presence of these complexes was independent of 
DNA damage. Association of mutant p53 with these promoters, dependent on 
the presence of NF-Y and CCAAT box integrity, was increased after adriamycin 
treatment, and the p300 HAT was then recruited in a manner that requires 
mutant p53. The switch between HDAC1 and p300 was accompanied by 
increased acetylation and reduced methylation of neighboring histones on the 
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cyclin B2 and cdk1 promoters. In contrast, wt p53 interacts with HDAC1 upon 
DNA damage to repress NF-Y target genes.  
Downregulation of the regulatory subunit NF-YA or mutant p53 led to 
impaired activation of the NF-Y target genes and reduced S phase accumulation 
after adriamycin treatment. Thus, the ability of mutant p53 to interact with NF-
Y and control important cell cycle regulatory genes represents new oncogenic 
gain-of function activity of mutant protein and specific recruitment of 
chromatin-modifying enzymes is responsible for this oncogenic potential 
(Fig.6). 
 
 
Figure 6. Transcriptional activities underlying mutant p53 gain-of-function (Peart and 
Prives, 2006). Model proposed by Di Agostino et al. (2006) in which the transcriptional 
regulation of NF-Y target genes by wt and mutant p53 are opposite following DNA 
damage due to the recruitment of opposing chromatin-modifying enzymes, conferring 
oncogenic “gain-of-function” properties to mutant p53 proteins. 
 
Remarkably, this gain-of-function activity seemed to be independent of 
the particular type of p53 mutation since different p53 mutations (p53His175, 
p53His273, p53Gly281) have been tested. In this paper the authors used both a 
DNA contact point mutant and a conformational mutant but it would be 
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interesting to confirm the universality of their observations by testing a wider 
spectrum of p53 mutations.  
 In summary, Di Agostino’s report provide mechanistic insights into 
mutant p53 gain of function activity by interaction with NF-Y and facilitation of 
NF-Y proliferative target genes transactivation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Aims of the Project 
1) The p63 protein is the “master regulator” of epidermal 
development, working with other proteins to closely coordinate the expression 
of genes that control cell growth and differentiation. Our lab has been involved 
in the identification of p63 targets in human keratinocytes, either by expression 
profiling or by ChiP on ChiP analysis (Testoni et al., 2006; Viganò et al., 2006). 
Klf4 is a transcription factor required for establishing the barrier function of the 
skin. Immunocytochemical analysis and expression data in mouse and human 
demonstrate strong evidence that p63 and KLF4 protein are localized in the 
different regions of the skin – while p63 is restricted to the basal cells, KLF4 is 
normally expressed in the granular and subcorneum strata. Thus, the project was 
dedicated to the study of possible KLF4 regulation by p63 in the normal 
keratinocytes and immortalized HaCaT keratinocytes that harbour 2 mutant 
alleles of p53. 
Results of the first part of the research demonstrate, that p63 is a 
repressor of KLF4 in the normal keratinocytes and this regulation is altered in 
the presence of mutant p53 in the HaCaT cells – upon these cellular conditions 
mutant p53 shifts p63 from repressive to activating sites at the KLF4 promoter, 
thereby, rendering p63 as an activator rather than repressor of KLF4 expression. 
Thus, we show that H179Y and R282Q p53 mutants possess gain-of-function 
activity (Publication 1). 
2) These results inspired us to investigate mechanisms of mutant 
p53 gain-of-function. Our preliminary data demonstrated that inactivation of 
mutant p53 in the human HaCaT keratinocytes leads to significant decrease in 
cell growth rates. Therefore, to understand the role of mutant p53 in cellular 
proliferation we have to perform ChiP-Seq experiments to discover mutant p53 
whole-genome DNA binding. Study of KLF4 promoter revealed mutant p53 as a 
p63 assistant in its programme of transcription regulation and analysis of mutant 
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p53 binding to DNA can shed light on other transcription factors partners. 
Moreover, the question whether mutant p53 binds DNA directly or by 
interaction with other proteins, is still open. To solve this and other problems 
Chip-Seq experiment with following bioinformatics analysis should be 
performed (Publication 2). 
3) At the previous stage of research we discovered that mutant p53 
alleles of the HaCaT keratinocytes confer growth advantages to the cells, i.e. 
possess gain-of-function activity. Although mutations of p53 were shown to 
contribute to tumor initiation, promotion, aggressiveness and metastasis, in the 
case of human immortalized keratinocytes it’s evident that this genetic alteration 
is not sufficient to render the cells malignant. Therefore, this part of the project 
was devoted to the development of the experimental model for the tumorigenic 
conversion of transformed but non-tumorigenic HaCaT cells. Sphere-forming 
assay is extensively used for the isolation and propagation of the cancer stem 
cells from the tumor bulk, so we decided to apply the same protocol for isolation 
of the HaCaT subpopulation that can resemble somehow tumor-initiating cells 
(Manuscript in preparation). 
4) Although the molecular mechanisms are still unclear, there is no 
doubt that interaction of p53 with NF-Y contributes remarkably to the cell cycle 
regulation and apoptosis upon DNA damage. Previous reports investigated the 
consequences of NF-YB inactivation and by the moment little is known about 
NF-YA role in the processes of p53-mediated apoptosis and cell cycle 
progression. This can be explained partially by the fact, that till now all 
experiments on NF-YA overexpression and/or inactivation were not 
successfully and no one report provide evidence about existence of the stable 
clones overexpressing NF-YA. This negative result didn’t discourage us and we 
decided to perform overexpression experiments in the different cell lines, taking 
into account that success of the experiment can depend on the p53 status. For 
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this purpose we employed wt p53, null p53, mutant p53 and p53 inactivated by 
the large T antigen cells.  
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Main Results 
1) Mutant p53 subverts p63 control over KLF4 expression in 
keratinocytes 
p63 protein is a p53 homolog and TF that plays a key role in the skin 
development (Dai and Segre, 2004). In two independent genetic experiments on 
p63 deficient mice it was demonstrated that these mice lack stratified epidermis, 
producing a disorganized singlelayered surface epithelium that was negative for 
epidermal markers such as keratin K5 and K14 (Mills et al., 1999; Yang et al., 
1999). Although the interpretation of the p63 mechanisms is still controversial, 
there is a strong experimental support that p63 is an epidermal master regulator.  
Transcription factor Klf4 is expressed mainly in the suprabasal layers 
of the epidermis and it’s a distinct marker of terminal differentiation. Klf4 is 
necessary for the establishment of the functional permeability barrier since 
KLF4 inactivation results in a loss of barrier and ectopic expression of KLF4 in 
the basal layer of skin promotes barrier acquisition in a dose-dependent manner 
(Jaubert et al., 2003; Segre et al., 1999). Immunohistochemical stainings of the 
mouse and human skin clearly demonstrate that expression of p63 and KLF4 
proteins is restricted to different regions of the skin: while p63 is expressed in 
the nuclei of epidermal basal cells (Di Como et al., 2002; Reis-Filho et al., 
2002), KLF4 is most highly expressed in the post-mitotic, differentiating 
epithelial cells of the skin (Garrett-Sinha et al., 1996).  
Our data demonstrate that KLF4 expression is increased upon in vitro 
differentiation – as p63 decreased. Differentiation of neonatal human 
keratinocytes was induced by addition of CaCl2 in medium and the success of 
the process was controlled by monitoring the levels of involucrin expression, 
which is well-known marker of keratinocytes terminal differentiation (Watt, 
1983), and p21, whose induction was observed in several in vitro terminal 
differentiation systems (Missero et al., 1996), as well as in differentiating tissues 
in vivo (el-Deiry et al., 1995; Parker et al., 1995). During differentiation KLF4 
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increases at both protein and mRNA level with the highest levels after 10 days. 
In parallel, ΔNp63α is progressively reduced. Immunofluorescence stainings 
confirmed increase of KLF4 expression, concomitant with p63 decrease, in 
neonatal keratinocytes and also in normal human adult skin KLF4 expression 
was observed at the low in the basal layer of the skin, increasing in subcorneum 
stratum with maximum at the upper layers, opposite to p63. Thus, KLF4 is 
activated upon keratinocytes differentiation in vitro and is mostly present in the 
cells with low levels of p63. 
At the next stage of research we provide evidence that p63 represses 
KLF4 in normal keratinocytes. Inactivation of p63 by siRNA, that recognize all 
6 isoforms, leads to up-regulation of KLF4 at both protein and mRNA levels in 
neonatal and adult human keratinocytes.  In silico analysis of KLF4 promoter 
revealed 9 putative p63/p53 binding sites and chromatin precipitation 
experiment showed p63 binding to (-2225), (-1784), (+467) regions and no p53 
binding. As positive control for the ChiP experiment we used C40 enhancer of 
p63 promoter that was demonstrated to be strongly bound by p63 in vitro 
(Antonini et al., 2006). All together these results show that p63 directly 
represses KLF4 transcription by binding to discrete upstream regions in the 
promoter. 
Intriguingly, in the human immortalized HaCaT keratinocytes, that 
harbour two mutant alleles of p53, p63 does actually activate KLF4 expression: 
inactivation of p63 by introduction of siRNA leads to downregulation of KLF4 
at both protein and mRNA levels and overexpression causes an increase of 
KLF4 protein and mRNA levels. To make sure that this effect was achieved by 
transcriptional stimulation of KLF4 promoter by p63 we performed transfection 
of the construct, containing luciferase reported under KLF4 promoter, together 
with control siRNA and p63 siRNA: activation of KLF4 promoter was reduced 
upon p63 inactivation. Furthermore, transfection of the same construct with a 
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ΔNp63α vector caused strong upregulation of KLF4 promoter that indicates the 
transcriptional regulation of KLF4 promoter by p63.  
In addition, in ChiP experiment we observed p63 binding to KLF4 
promoter, but in the regions, different from those, observed in the neonatal 
keratinocytes. Moreover, in one region, containing p53/p63 responsive element, 
we also detected p53 bound together with p63 and this interaction wasn’t 
observed in normal keratinocytes.  
HaCaT cells harbour mutations of p53 genes in both alleles: C T 
transition at codon 179 (His Tyr) and a CC TT base change at codons 281 
and 282 (Arg  Trp) were identified (Lehman et al., 1993). Both mutations are 
located in DNA-binding domain and these changes are well-known UV hot 
spots (Brash et al., 1996). While in normal basal keratinocytes p53 is expressed 
at extremely low level (Pablos et al., 1999), mutant p53 is abundantly present in 
the HaCaT cells due to prolonged half-life compared with that of the wtp53 
protein (Lehman et al., 1993).  
We hypothesized that inversed regulation of the KLF4 promoter by p63 
could be a consequence of the mutant p53 action, especially after observation 
that mutant p53 was bound together with p63 on the KLF4 promoter. To clarify 
the role of mutant p53 in the regulation of KLF4 promoter we inactivated it by 
introduction of siRNA and observed reduction of KLF4 expression at the protein 
and mRNA levels. It worth mentioning that expression of p63 was unchanged 
upon these conditions and was always at the high level. This can indicate that 
KLF4 decrease wasn’t a secondary effect of the p63 protein level. Importantly, 
expression of the H179Y and R282Q p53 mutants in normal keratinocytes was 
sufficient to activate of endogenous KLF4 protein.  
Strong affinity of mutant p53 to p63 protein was proven in co-
immunoprecipitation assay in the HaCaT cells (Gaiddon et al., 2001). To 
elucidate whether these proteins collaborate on some discrete regions on KLF4 
promoter, we performed Chip and re-Chip experiment, using antibodies against 
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p53 and p63. Both mutant p53 and p63 were bound at the (-400) region on the 
KLF4 promoter. Altogether, these experiments indicate that p53 mutants have a 
direct positive effect on KLF4 expression, together with p63, by binding to a 
core promoter region of KLF4. 
Up to 90% of cutaneous SCC lesions have UV-induced signature 
mutations, in the p53 gene (Brash et al., 1991), resulting in accumulation of the 
p53 protein. Similarly, ΔNp63α was demonstrated to be expressed at the high 
levels in HNSCC (Choi et al., 2002; Crook et al., 2000). The role of KLF4 in 
different cancers is rather controversial, since it can act as a tumor suppressor 
gene or as an oncogene (Rowland et al., 2005). Tumor suppressor role of KLF4 
was observed in in human colon and gastric cancers (Wei et al., 2005; Wei et al., 
2006; Zhao et al., 2004), esophagus (Wang et al., 2002), lung (Hu et al., 2009), 
bladder cancers (Ohnishi et al., 2003) and T-cell leukemia (Yasunaga et al., 
2004). Conversely, KLF4 can function as a transforming oncogene. KLF4-
transformed rat kidney epithelial cells demonstrate morphologic transformation 
and increased tumorigenicity in athymic mice (Foster et al., 1999). In human 
HNSCC and breast cancer, increased KLF4 expression has been reported (Foster 
et al., 2000; Foster et al., 1999). Moreover, KLF4 expression has been 
demonstrated to be a poor prognostic factor for early breast cancer and skin 
cancer (Chen et al., 2008; Pandya et al., 2004) corroborating its oncogenic roles. 
Analysis of expression levels in a panel of different skin tumours by 
immunohistochemical stainings revealed robust p53 and KLF4 expression in the 
most of SCCs, whereas the expression of p63 was already high. Especially 
noteworthy is an observation that in the major part of the SCC investigated 
KLF4 was overexpressed together with p53. In conclusion, these data support 
the notion that an overexpressed, mutant p53 is involved in the positive 
regulation of KLF4 in human SCC.  
In summary, in this report we present evidence that KLF4 is negatively 
controlled by p63 in normal skin in the presence of physiological levels of wild-
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type p53, and that this regulation is subverted by oncogenic mutations of p53, 
establishing a direct link between these TFs, commonly overexpressed in SCCs. 
Because KLF4 overexpression cooperates in reprogramming differentiated cells, 
our findings have potential consequences for the mechanisms of formation of 
skin carcinomas. 
 
2) Gain-of-function p53 mutants have widespread genomic locations 
partially overlapping with p63 
All previous data encouraged us to investigate in vivo whole-genome 
DNA binding by mutant p53 and its functional activity. For this purpose we 
inactivated p53 in HaCaT cells by lentiviral transduction of the vector, 
expressing shp53 following puromycine selection and scramble shRNA as 
negative control. Recently, at least 12 different p53 isoforms were identified and 
data obtained from animal and cellular models indicate that p53 isoforms 
regulate the cell fate in response to developmental defects and cell damages by 
differentially regulating gene expression (Marcel et al., 2011). For this reason 
for inactivation experiment we used shRNA that targets DNA-binding domain 
of p53 to aim all possible isoforms of p53.  
Clones were readily selected, pooled and inactivation of p53 was 
controlled by qPRC and western blot. While mutant p53 mRNA level was 
significantly decreased and the protein level was essentially abolished, p63 
mRNA was decreased modestly. Remarkably, we never managed to inactivate 
p63 by shRNA introduction in the HaCaT cells, likely because the role of p63 in 
the growth and survival of these cells (unpublished data). 
With the clones obtained we have performed the experiments to 
understand the behavior of the p53-inactivated HaCaT cells in response to DNA 
damage. After UVB irradiation we observed a modest variation in cell cycle 
progression: increase in subG1 and G1 cells, and a decrease in G2/M in cells 
lacking mutp53. The degree of apoptosis, as measured by TUNEL assays, PARP 
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activation and Caspase 8 cleavage was lower in the absence of mutp53, but still 
present. Thus, other mechanisms compensate for the lack of mutp53 to drive a 
DNA-damage response.  
The most notable difference, however, was the growth rate, as curves 
were flatter in HaCaT deprived of mutp53. These data confirm that mutp53 are 
indeed gain-of-function alleles contributing to cellular growth. Thus, even if 
mutp53 was found to be non-functional regarding induction of apoptosis and 
cell cycle arrest, there is no doubt that it affects significantly the growth 
properties of the cells. 
To investigate the possible mechanism of mutant p53 gain-of-function, 
we performed analysis of DNA binding by p63 and mutp53 by ChIP-Seq 
experiment, using DO1 monoclonal antibody, recognizing the N-terminal 
domain of p53, and a polyclonal antibody against p63. We identified 7135 peaks 
for p53 and 3421 for p63 in HaCaT cells, defined as areas with a significant 
enrichment in the IP with respect to the corresponding genomic region of Input 
DNA controls run in parallel. We analyzed the locations and we found out that 
1591 mutp53 and 907 p63 sites reside in promoters, and 3697 and 1400, 
respectively, in the body of RefSeq genes. What’s important is that notorious 
p63 targets such as p21, Mdm2 were among the positive targets. We proceeded 
with validation of the ChiP-Seq data and performed ChiP experiment, using Ab7 
polyclonal antibody against p53 and 4A4 monoclonal p63 antibody and some of 
the positive regions were monitored by qPCR: with the exception of FANCi (1 
out of 13), the other targets were enriched. We noticed that some targets scoring 
positive only for p63 in ChIP-Seq were also somewhat enriched with Ab7, 
suggesting that we might be underscoring the overlap of the two TFs, possibly 
because DO1 is unable to pick up the shorter p53 isoforms present in HaCaT 
cells (Marcel et al., 2011). Finally, p63 targets previously identified as 
functionally important, such as KLF4, Notch1, TP63, DLX3/4 and JAG2, 
among others, scored positive for p63 and mutp53. 
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We therefore felt confident to analyze the ChIP-Seq locations and found 
the expected overrepresentation in promoters, from -5000 to +1000 of the 
Transcriptional Start Sites: 1591 mutp53 and 907 p63 sites reside in promoters, 
and 3697 and 1400, respectively, in the body of RefSeq genes. We characterized 
the overlap between positive peaks and found out that 19% of p63 peaks overlap 
with mutp53 in the promoter (175 out of 907) and 17% in the body of genes 
(240 out of 1400). 
Next, we evaluated the enrichment of TFBS in the p63
+
, mutp53
+
 and 
p63/mutp53
+
 peaks with a width of 150 bp from the center with the Pscan 
software (Zambelli et al., 2009), using as background a set of 10.0000 sequences 
of the same size, chosen at random from genomic regions annotated either as 
“promoter” or “enhancer”. It is apparent that a consensus p53/p63 responsive 
element is at the top of the list in p63
+
 and p63/mutp53
+
 peaks, but not in 
mutp53
+
, where sites of other TFs predominate: E boxes, variously termed 
NHLH1, Myf, Mycn, USF1, MYC-MAX, MAXESR (nuclear receptors), AP2. 
This is an indication that p63, either alone or with mutp53, recognizes its own 
site, whereas mutp53, in the absence of p63, binds DNA through sequences 
recognized by other TFs. 
We then used the Weeder software (Pavesi et al., 2004) to perform de 
novo motif discovery in the peaks of the three cohorts, in promoters, genes or 
elsewhere: a TGGGCATGTC sequence clearly emerged in p63
+
, containing a 
perfect p53/p63 consensus with additional information on the flankings; a 
similar sequence, lacking the CC at the 3’ end, is recovered in p63/mutp53+ 
locations; in mutp53
+
 peaks, instead, the variety of underlying sequences 
prevented the emergence of a clear consensus by de novo analysis, confirming 
the underlying presence of several unrelated TFBS. 
A large number of genomic locations of p63 have been recently 
discovered in primary keratinocytes using the same antibody employed in our 
study (Kouwenhoven et al., 2010). We analyzed the data of primary human 
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keratinocytes and HaCaT cells and found that a substantial number (50%) of 
HaCaT locations are missing in primary keratinocytes (PHK). We assessed the 
number of mutp53 peaks in the two populations and found some skewing: 222 
were in the PHK common sites, and 367 in the HaCaT-only cohort, suggesting 
that the presence of mutp53 alters p63 binding to a subset of sites bound in 
normal keratinocytes.  
Gene Ontology analysis retrieved terms such as organ morphogenesis, 
tissue and epidermal development and positive regulation of transcription in 
p63
+
 devoid of mutp53; the same terms were present in the larger p63
+
 cohort, 
with the addition of Wnt signaling and induction of apoptosis. Terms related to 
signal transduction and cell cycle were prevalent in mutp53
+
 genes. Specifically, 
the mutp53/p53
+ 
sites were enriched in terms of Wnt signalling and other 
metabolic terms in the molecular function analysis, such as actin binding, 
Tyrosine Kinase and GTPase activity. In addition to previously characterized 
targets families of targets worth mentioning are Wnt genes -Wnt4, Wnt7a, 
Wnt9a, Wnt10aand Retinoic Acids Receptors, RARα, RARγ and RXRα. Both 
p63 and mutp53 are present at multiple locations of the large cluster of keratin 
genes on chromosome 17. From this set of data we conclude that p63 binding in 
HaCaT is different from PHK, in part due to the presence of mutp53. 
Next, we performed profiling analysis of mutp53 inactivated HaCaT 
cells. A large number of genes were up -1649- or down -1644- regulated, by 
using a relatively stringent cut-off ratio of 1.5-fold. We characterized the 
overlap between positive peaks, and found that 19% of p63 peaks overlap with 
mutp53 in the promoter (175 out of 907) and 17% in the body of genes (240 out 
of 1400). We validated the profiling results by qRCR: essentially all genes 
changed expression according to expectations. The overlap between the mutp53 
locations and gene expression analysis is 15%. GO categorization identified cell 
cycle, as well as DNA and RNA metabolisms and response to DNA damage as 
robustly enriched in the upregulated cohorts, in the downregulated genes, p-
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values were less significant with sterol biosynthesis and keratinocyte 
differentiation being somewhat enriched.  
Our work addresses a debated topic concerning the mechanisms of action 
of gain-of-function mutant p53 and p63. We found that mutp53 HaCaT alleles 
are pro-growth and mutp53 have thousands of binding sites in the human 
genome; they affect gene expression profoundly, both by binding with p63 to 
consensus elements and by being tethered by other TFs to their locations. 
 
3) Spheres from HaCaT: a model for skin cancerogenesis 
 In the previous stage of research project we established that 2 mutant 
alleles of p53 (H179Y and R282Q) in the HaCaT immortalized keratinocytes are 
pro-growth and display gain-of-function activity (Martynova et al., 2012). 
Although p53 is the key player in the cellular program of tumor suppression and 
it’s mutated in more than 50% of the human tumors (Vogelstein et al., 2000), 
this genetic alteration of the p53 gene is not enough to render this cells 
tumorigenic – HaCaT cells are immortalized human keratinocytes that don’t 
give rise to the tumors upon injection into immunocompromised mice 
(Boukamp et al., 1988). As it was mentioned above, tumorigenic conversion of 
the HaCaT cells can be achieved by transfection of ras oncogene (Boukamp et 
al., 1990), upon prolonged cultivation in serum-free medium (Hill et al., 1991), 
and at elevated temperature (Boukamp et al., 1997), by repeated subcloning with 
forced proliferation (Fusenig and Boukamp, 1998) and by activation of the 
stromal environment (Skobe and Fusenig, 1998).  We decided to established 
novel, simply model for the HaCaT oncogenic conversion that can be useful for 
the future studies of the genetic and phenotypic changes upon skin tumor 
development. 
Currently there are 2 models of tumor development: the clonal evolution 
model suggests that within a population of tumor cells a natural selection occurs 
that favors cells that have acquired (e.g., through additional mutations) the most 
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aggressive phenotype (Nowell, 1976). Essentially, this hypothesis assumes that 
all cells within a tumor hold an equal potential to maintain and advance the 
tumor to metastasis. Unlike clonal evolution hypothesis, the model of cancer 
stem cells (CSC) postulates that malignant tumors are initiated and maintained 
by a small population of cells within a tumor, and these cells possess properties 
similar to normal adult stem cells - the ability to self-renew and generate 
differentiated progeny (Wicha et al., 2006).  
Existence of the minor subpopulation with enhanced tumorigenic 
potential was demonstrated also for the established cancer cell lines: rat C6 
glioma (Kondo et al., 2004), U373 glioma and MCF7 breast cancer cells 
(Patrawala et al., 2005), different breast cancer cell lines (Charafe-Jauffret et al., 
2009), HT29 and SW1222 colorectal cancer cell lines (Yeung and Mortensen, 
2009). The heterogeneity of the cellular composition also was found within 
culture of human keratinocytes: colony-forming epidermal cells possess 3 clonal 
types with different proliferating potential (Barrandon and Green, 1987). One of 
them, holoclone, had the greatest reproductive capacity and holoclone-forming 
cells are multipotent stem cells (Claudinot et al., 2005).  
Nowadays there 3 different strategies for isolation and propagation of the 
stem-cell like cells from normal and tumor tissues: establishment culture, the 
magnetic cell sorting (MACS) and the fluorescence-activated cell sorting 
(FACS) technologies. Sphere-forming assay originally was established for the 
isolation of the stem cells from central nervous system (Reynolds and Weiss, 
1992) and currently is widely used for the CSC selection from brain (Lee et al., 
2006), breast (Dontu et al., 2003), colon (Ricci-Vitiani et al., 2007), prostate 
(Sullivan et al., 2010), ovarian cancer (Zhang et al., 2008) and melanoma (Fang 
et al., 2005). 
In the current study to examine the heterogeneity within the culture of 
human keratinocytes and existence of tumor-initiating cells we applied sphere-
forming assay: HaCaT cells were plated at the low density (<10 000 cells/6 
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well) in specific medium into ultralow adhesion flasks. The serum-free medium 
is supplemented with several factors, in particular, bFGF and EGF. After 3-4 
days in these culture conditions HaCaT keratinocytes were able to form 
nonadherent, multicellular aggregates that we termed keratospheres. It’s well 
known that growth and survival of the epithelial cells depend drastically on cell-
cell and cell-matrix interactions. Disruption of the substrate adhesions in normal 
epithelial cells leads rapidly to programmed cell death (Frisch and Screaton, 
2001), so epithelial cells in culture once detached from the tissue culture surface 
normally undergo anoikis. In defined medium keratospheres could be serially 
passaged for more than 55 passages (more than 1 year in culture) (Part III, 
Fig.1a). Interestingly, we couldn’t obtain keratosphere culture in ultra-low 
attachment plastic in conventional DMEM for more than 4 passages. Thus, the 
components of the defined medium are essential for the sphere propagation.  
Comparison of the growth characteristics of the keratospheres and its 
parental HaCaT cell line by trypan blue exclusion method demonstrates that 
spheres-forming cells grow significantly slower than parental HaCaT cells (Part 
III, Fig.1b). 
The analysis of cell growth characteristics demonstrated that 
keratospheres in comparison to parental HaCaT cells contain infrequently 
dividing cells with enhanced capacity to self-renewal (Part III, Fig. 3). This 
description somehow resembles epidermal stem cells, as Potten et al. argued that  
under normal conditions in vivo, epidermal stem cells are believed to divide 
infrequently and to have a long cell cycle time (Potten and Morris, 1988). We 
would like also to emphasize that with increase in keratosphere passage number 
we could observe morphologic changes of the colonies and its number: larger 
colonies could be observed for high passage keratospheres and also more 
colonies were formed for this cells.  
Phenotypic characterization of the cells revealed heterogeneity within 
keratospheres (Part III, Fig.2): floating spheres showed widely diffuse staining 
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for p63, KRT1, KLF4, which represents differentiated keratinocytes, but 
interestingly, the cells with enhanced expression for the main basal keratinocyte 
markers (α6-integrin and KRT14) are located on the perimeter of  the spheres, 
thus indicating that 1) keratinocytes are heterogeneous aggregates, containing 
both differentiated and undifferentiated cells 2) certain orientation for the 
keratosphere growth exists: growth vector is directed from the external part of 
the sphere to the central part, as keratospheres grow from outside to inside.  
But the most significant alteration we observed is an acquisition of the 
keratospheres a capacity to grow in the soft agar in comparison to the parental 
HaCaT keratinocytes, i.e. the finding that keratospheres became anchorage-
independent (Part III, Fig. 4a). HaCaT keratinocytes commonly demonstrate 
rather inefficient growth in soft agar (Boukamp et al., 1988), but keratospheres 
showed enhanced growth upon these conditions. The internal control of the 
experiment was also included: HaCaT cells growing in soft agar in the 
keratosphere medium (HaCaT + MEGM) didn’t demonstrate transformed 
phenotype in this experiment. To establish whether the components of defined 
medium could cause the tumorigenic conversion of the immortalized 
keratinocytes, HaCaT cells were grown in the defined serum-free medium in the 
tissue culture flasks for 4 passages and then soft agar assay was performed 
again: as present in the Fig. 4a (Part III) even in this case cells still remained 
non-tumorigenic since after 4 passages in the keratosphere medium cells failed 
to form the colonies in the soft agar. 
Deserving attention the fact that keratospheres acquired the tumorigenic 
potential not immediately but after growing for some passages (we observed 
firstly colonies in soft agar after 8 passages in the culture) (Part III, Fig.4b). As 
in the case of colony-forming assay in this kind of experiment we also observed 
the morphological difference of the colonies obtained: higher was the number 
passage of keratospheres, bigger colonies we could observe.  
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It’s well known that there is reasonably good correlation between in vitro 
transformation and in vivo carcinogenesis, but it’s not necessarily the case of the 
skin carcinoma cells (Boukamp et al., 1985). Xenotransplantation into immuno-
compromised mice was performed in vivo assay to demonstrate tumorigenicity 
of keratospheres. Although immortalized HaCaT cell line exhibited a 
transformed phenotype in vitro, cells were not tumorigenic after subcutaneous 
injection: in the original manuscript P. Boukamp (Boukamp et al., 1988) 
demonstrated that HaCaT cells after subcutaneous injection onto athymic nude 
mice developed large encapsulated cysts often filled with horny squames. On 
the contrary, keratospheres of the high passage developed well differentiated 
squamous cell carcinoma (Part III, Fig. 5). Thus, in this study we demonstrate 
that performing sphere-forming assay of HaCaT keratinocytes leads to the 
oncogenic conversion of the immortalized keratinocytes to the tumorigenic 
phenotype.  
50% of the head and neck squamous cell carcinoma (HNSCC) cases 
harbor mutations in the p53 tumor suppressor gene (Poeta et al., 2007). In 
HNSCC mutation renders p53 inactive and this state of mutant p53 is associated 
with tumor progression and decreased overall survival (Poeta et al., 2007). 
HaCaT cells harbor both alleles of the p53 gene mutated (Lehman et al., 1993) 
and identified C→T transition at codon in position 179 and CC→TT base 
changes at codons 281 and 282 are well-known UV hot spot mutations. It’s 
supposed that biopsy for the HaCaT cell line establishment was obtained from 
the sun-exposed area and these mutations have been already occurred in the 
patient. Mutation of the p53 gene can be one of the reasons for the 
immortalization of the human keratinocytes and it’s possible that absence of 
functional p53 protein can lead to the genomic instability and facilitate 
oncogenic conversion of the HaCaT keratinocytes to the tumorigenic 
keratospheres. 
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We focused on analysis of gene expression patterns in HaCaT cells 
versus SCC developed in mice. Gene expression profiling (GEP) provided us 
the list of genes with altered expression, which are associated with cell cycle 
regulation, differentiation, cell division, epidermis development (Part III, 
Fig.6b). Injection of the keratospheres into immune-compromised mice led to 
the formation of well-differentiated SCC, and GEP analysis confirmed the 
overexpression the classical keratinocyte differentiation markers – KRT10, 
KRT1, Filaggrin, Loricrin, TGM5 (Part III, Fig. 6a, b). During differentiation 
process keratinocytes withdraw from the cell cycle and in Gene Ontology 
analysis category “cell cycle” is present in the list of the down-regulated genes 
with high p-value.  
Interestingly, we found members of the matrix metaloprotease family 
(MMP-1, MMP-3, MMP10),  Laminin-γ2 (LAMC2), KRT17, IFI6 , PLAU, 
among highly up-regulated genes and  KRT4, MAL, SCEL are  significantly 
down-regulated in SCC, as it has been already demonstrated in numerous 
studies (Yu et al., 2008; Ziober et al., 2006). It’s well documented that Wnt-
pathway is frequently impaired in colorectal, thyroid, hepatocellular, melanoma 
cancers (Polakis, 2012), but contribution of this pathway in the HNSCC is still 
unclear. However there are indications that Wnt pathway is also altered in oral 
cancers. Leethanakul et al. discovered that most HNSCC overexpress members 
of this signaling pathway: several wnt receptors, and their downstream targets, 
dishevelled and β-catenin are highly expressed in comparison with normal tissue 
(Leethanakul et al., 2000). The overview of the dysregulated signaling 
pathways, involved in the acquisition of the oncogenic characteristics by HaCaT 
keratinocytes, revealed up-regulated Wnt pathway. This result underlines a 
potential relevance of Wnt pathway in HNSCC.  
Several reports indicate the hedgehog-signalling pathway is involved in 
the proliferation of the SCC (Koike et al., 2002; Schneider et al., 2011). Our 
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analysis showed elevated pathway activation in the examined malignant tissue 
compared to the control samples.  
Yu et al performed a genomic meta-analysis of 41 HNSCC gene 
expression profiles and the list of most frequently misregulated genes arised 
(Lallemant et al., 2010; Yu et al., 2008). Interestingly, the comparison of our 
microarray data (HaCaT vs. Tumor) revealed 17 genes out of 25 (68%) 
intersecting with the genes of the list, comparing HNSCC versus normal mucosa 
(Part III, Suppl.1). 14 out of 25 (56%) - 3 down-regulated and 11 up-regulated 
genes demonstrated similar behavior upon tumorigenic transition from HaCaT 
cells to SCC in our experiment. It’s worth mentioning the presence of matrix 
metalloproteinase-1 (MMP1), ITGA6 from integrin signalling pathway, 
extracellular matrix protein 1 (ECM1), keratin 13 (KRT13), KRT17, KRT4 in 
the list of highly reported genes. Laminin-γ2 (LAMC2) is frequently 
overexpressed in HNSCC (Patel et al., 2002) and in the future studies it should 
be considered as predictor of the SCC development.  These putative 
transcriptional biomarkers after validation on patients can be useful for the 
clinical diagnostics in the future. 
Upon cultivation of the human immortalized, non-tumorigenic 
keratinocytes we observed oncogenic transition to the keratospheres that were 
able to form SCC in the nude mice. Molecular mechanisms of such transition 
are still unclear, but 2 models can be hypothesized: 1) prolonged passaging of 
the HaCaT cells in sphere-defined medium leads to the specific selection of the 
cells with enhanced tumorigenic potential from the heterogeneous culture; 2) 
culturing in the defined medium in the form of non-adherent clusters results in 
up/down regulation of the certain pathways that leads to the tumorigenic 
conversion. Although we have to perform future experiments to understand the 
mechanisms that underlie oncogenic transition for keratospheres, such model 
seems to be simple and attractive for investigation of the molecular signatures of 
the SCC. 
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4) Role of NF-YA in the processes of cellular proliferation and 
apoptosis 
The NF-Y complex is a key player in the regulation of cell 
proliferation, supporting basal transcription of numerous cell cycle genes (Kabe 
et al., 2005; Wasner et al., 2003). Additionally, NF-Y plays a pivotal role in the 
DNA-damage response, mediating the p53-dependent repression of G2/M genes 
(Imbriano et al., 2005). Moreover the role of NF-Y in the process of the 
programmed cell death has recently emerged:  Gurtner et al. demonstrated that 
unrestrained NF-Y activity promotes apoptosis depending on E2F1 induction 
and wtp53 activation (Gurtner et al., 2010). It’s worth mentioning that in the 
inactivation experiments of single NF-Y subunit (NF-YA or NF-YB) was 
perceived by cells in the different way, activating diverse cell cycle blocks and 
signalling pathways (Benatti et al., 2011). The importance of NF-Y is further 
underscored by the early embryonic lethality of an NF-YA mouse knockout 
model due to defects in cell proliferation and extensive apoptosis (Bhattacharya 
et al., 2003). 
The genome-wide analysis of NF-Y binding in K562, GM12878 and 
HeLa S3 tumor cell lines within ENCODE project found that NF-Y 
preferentially associates with genes involved in the inter-related p53 and TRAIL 
apoptotic pathways (Fleming et al., 2013). This observation reinforces the 
notion of a direct and indirect NF-Y/p53 interplay, with opposing functional 
consequences depending on the p53 status of the cell, i.e. proliferation or 
apoptosis (Imbriano et al., 2012).  
While performing experiments on NF-YA inactivation/overexpression 
we and other research groups experienced difficulties to obtain stable clones 
with NF-YA overexpressed/silenced. Gurtner et al. explained this result by the 
fact that when NF-YA is overexpressed in the wtp53 cellular context, cells 
undergo apoptosis (Gurtner et al., 2010). 
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Preliminary data of our collaborators (Imbriano, Mantovani, manuscript 
in preparation) indicate that transient inactivation of the NF-YA subunit leads to 
the diverse outcomes in the cells with different p53 status: while cells with 
wtp53 (or wtp53 with reduced stability due to enhanced ubiquitination by virally 
encoded E6 protein, resulting in its accelerated degradation –case of HeLa cells)  
upon knock-down of NF-YA undergo apoptosis, cells harbouring mutant p53 
alleles or p53 null cells demonstrate enhanced resistance to the programmed cell 
death. 
We took a decision to perform an opposite experiment and overexpress 
NF-YA subunit. Since we have already seen in the inactivation experiments the 
importance of the p53 status, diverse cell lines were chose: wtp53 (HT1080 
fibrosarcoma, HCT116 wt colon carcinoma, HepG2 human liver hepatocellular, 
MEF mouse embryonic fibroblasts), p53 null (PC3 human prostate 
adenocarcinoma, HCT116 p53 -/- colon carcinoma), mutant p53 (T98G human 
glioblastoma, HaCaT human immortalized keratinocytes, A431 epidermoid 
carcinoma), HEK293T (human embryonic kidney cells, transformed by 
expression of the large T antigen from SV40 virus).  
We cloned the long and short forms of NF-YA cDNA from the plasmid 
vectors, kindly provided by Li et al. (Li et al., 1992a) into pSin-EF2-Sox2-Pur 
lentiviral vector (Addgene, #16577) via restriction digest with EcoRI and 
BamHI enzymes. Also dominant negative mutant forms of both NF-YA 
isoforms were cloned in the same vector backbone. This mutation is a triple 
amino acid substitution in the DNA binding domain that impairs its ability to 
bind DNA. It is still able to interact with a NF-YB/-YC dimer, but the resulting 
trimer is inactive in terms of CCAAT recognition (Mantovani et al., 1994).  
For the production of lentiviral particles transient transfection of 293T 
cells with a 2nd generation packaging system was applied (lentiviral vector, 
containing transgene, packaging vector pCMV-dR8.2- dvpr, an envelope vector 
pCMV-VSVG). The lentiviral infection was performed by double spinoculation 
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of the cells (1h centrifugation, 2000 rpm, with a 5h interval) in the pure viral 
supernatant in the presence of 2 μg/ml polybrene. 72 h after infection 
puromycine (Sigma, USA) was added in the medium for the selection (the right 
concentration of the antibiotic was established before for each cell line). Empty 
pSin-EF2 -Pur vector served as a negative control. The efficiency of the 
lentiviral transduction was controlled by additional infection of the cells with 
GFP lentivirus. After 1-2 weeks in the selection medium stable clones were 
pooled and the expression level of the transgene was monitored by Western blot.  
By the moment lentiviral transduction of 9 different cell lines (+293T 
cells – work in progress) was performed and the results are present in the Figure 
7 (Part II). First of all we controlled p53 status in the following cell lines: wtp53 
is known to be expressed at the low levels in the normal cells due to relatively 
short half-life (∼10–20 min) and mutant p53 is characterized by a prolonged 
half-life compared with wtp53 protein (Cadwell and Zambetti, 2001). In 
accordance with IARC TP53 Database (http://p53.iarc.fr/) PC3, HCT116 p53 -/- 
are p53 null; HT1080, HCT116 wtp53, HepG2, MEF have wtp53; T98G, A431, 
HaCaT harbour mutant p53. Verification of the different NF-YA isoforms in 
these cell lines demonstrate that HepG2, A431, HCT116 wtp53, HCT116 p53 -/-
express short isoform, while T98G and HT1080 have long NF-YA isoform and 
PC3 express both forms. 
 All lentiviral transduction experiments were repeated three times. The 
results of the overexpression experiments are present in the Figure 8 and 
summarized in the Table in the Figure 7 (Part III). First of all, it’s intriguing that 
in contrast to the previous experiments we finally succeeded to obtain stable 
clones from some cell lines. We can assume that failure of the preceding 
experiments was due to the low number of the cell lines examined. You can 
easily see that overexpression experiment was successful just in 5 cell lines out 
of 10. Furthermore, it’s interesting that not all isoforms could be overexpressed: 
it’s obvious that NF-YA short isoform (YA1) has some advantages comparing 
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to the long isoform (YA13) and can be expressed easier in the following cell 
lines. 
At the moment we can’t draw any conclusion about connection 
between p53 status and NF-YA overexpression, since we obtain stable clones 
for wtp53, mutant p53, p53 null cells. Moreover this effect can be cell specific.  
On-going experiments are focused on characterization of the stable 
clones: first of all we compared the growth characteristics of the cells. There is 
growing body of evidence that short and long NF-YA isoform are functionally 
diverse (See 4.2. “State of Art”). Evaluation of cellular proliferation using the 
MTT assay clearly demonstrate that NF-YAs confers growth advantage in 
comparison to the cells, expressing empty vector (HCT116 wt, U2OS) and also 
in comparison to the cells overexpressing NF-YAl isoform (HaCaT, HT1080). 
The same effect of the short NF-YA isoform on the cell proliferation has been 
already observed in our laboratory in the experiments on the mES (Dolfini et al., 
2012b).  
 Thus, at this stage of research project we established several cell lines 
overexpressing different isoforms of NF-YA and some of the NF-YA mutants. 
Future experiments will be performed to understand the behaviour of the cells 
upon DNA damage, serum starvation, wound healing. Since HaCaT cells 
represent well characterized model for the keratinocyte differentiation stable 
HaCaT clones will be checked for the ability to undergo normal differentiation 
by Ca
2+
 induction.  
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Conclusions and Future Prospects 
 In the first part of research we established the link between 3 
transcription factors: p63, KLF4 and mutant p53. Based on the results achieved 
we put forward a hypothesis that mutant p53 hijacks p63 from repressive to 
activating sites on the KLF4 promoter, radically changing KLF4 regulation at 
the transcription level. These results are even more intriguing in the light of 
Takahashi’s landmark discovery that KLF4 is one of the transcription factors, 
indispensable for the reprogramming of the differentiated cells into iPS 
cells(Takahashi and Yamanaka, 2006). We and other research groups 
demonstrated that KLF4 is present at the high levels in SCC, where ΔNp63α and 
mutant p53 are already overexpressed (Deyoung and Ellisen, 2007). Since we 
discovered the mechanisms by which KLF4 is maintained at the high levels in 
the SCC, in the future we have a new field of research open to get inside the 
genesis of the cancer. A group of transcription factors is capable to reprogram 
differentiated cells into iPS cells, so the current hypothesis that tumours are 
derived from stem cells should be revised, as reprogramming of already partially 
differentiated cells, in the context of various genetic alterations, could also lead 
to tumor formation. Presence of the mutant p53 in the human keratinocytes 
donates to the cells growth advantages by targeting a gene with reprogramming 
capacity. The mechanistic details of the KLF4 role in normal keratinocytes 
versus SCC will be understood once its targets are unravelled by genome-wide 
approaches. 
 The results obtained for the regulation of KLF4 expression by p63 and 
mutant p53 inspired us to investigate the whole-genome mutant p53 binding in 
human keratinocytes. We found out that mutant p53 can alter profoundly gene 
expression by binding not just to p63 but to other transcription factors. The 
future experiments can be focused on identification of other mutant p53 partners 
that recruit mutant p53 to DNA. Moreover, since it’s already known that not all 
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p53 mutants are functionally equal, it would be also interesting to study gain-of-
function in the different cellular context – in the cells harbouring different p53 
mutants.  Since it’s already well documented that different p63 and p73 isoforms 
have divergent biological properties, it would have sense to examine the mutant 
p53 interaction with p63 and p73 in the context of p63, p73 isoforms diversity. 
 We provided clear evidence that mutant p53 alleles of the HaCaT cells 
possess gain-of-function activity and confer enhanced proliferative potential to 
the cells. However this genetic alteration is not sufficient to render these cells 
oncogenic. In the 3rd part of the project we described a model for the skin 
cancerogenesis based on the sphere forming assay and HaCaT keratinocytes: 
growing cells in the floating spheres in defined serum-free medium leads to the 
formation of the keratospheres, that in comparison to the parental HaCaT cells 
display transformed phenotype and moreover give rise to the SCC when injected 
into nude mice. Microarray analysis revealed numerous genes whose expression 
is changed upon transition from the HaCaT cells to the keratospheres and finally 
to the tumour sample. More detailed analysis of the data can discover candidates 
for the SCC biomarkers that should be verified on the patients. Thus, sphere-
forming assay of the HaCaT keratinocytes represents a simple, relatively 
inexpensive, not time-consuming model for study of the phenotypic and genetic 
alterations that occur upon initiation and development of SCC. 
 Transcription factor NF-Y plays a crucial role in the control of cell cycle 
progression and actively participate in the response of the cell to DNA damage 
via invitation with p53. Recent reports also underlie the importance of the NF-Y 
in the process of the programmed cell death. On-going project is dedicated to 
the investigation of NF-YA subunit function in the processes of cellular 
proliferation and apoptosis. By the moment several stable clones overexpressing 
different isoforms of NF-YA were obtained and future experiment will be 
focused on the characterizations of these clones in terms of response to DNA 
damage, serum starvation, wound healing and differentiation.  
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Figure legends 
 
Figure 1: Development of keratospheres (A) Schematic representation of the 
keratospheres culture establishment: HaCaT cells form anchorage-independent 
spheres in defined serum-free medium supplemented with bFGF and EGF. 
Phase contrast photographs of the keratospheres derived from human HaCaT 
keratinocytes at the passages 2, 6, 32, 36; ×60 objective; (b) Comparison of 
growth rates for keratospheres and parental HaCaT cells by direct counting of 
the viable cells. 
 
Figure 2: Phenotypic characterization of the HaCaT-derived spheres.  
Immunostaining of intact keratospheres analyzed by confocal laser scanning 
microscopy. Photographs represent positive immunostainings for p63, Klf4, α6-
intergrin, CK1, CK14.  DAPI staining was included to identify nuclei. 
 
Figure 3: Keratosphere reproductive capacity. (A) Comparison of in vitro 
clonogenecity of the parental HaCaT keratinocytes and keratospheres. 1000 
single cells of each cell line were plated at 100 mm tissue-culture Petri dish and 
cultured for 2 weeks. At the end of experiment cells were stained with Giemsa, 
photographed, and analyzed for their proliferation efficiency. (B) Quantitative 
representation of the colony-forming assay, performed in triplicate.  
 
Figure 4: Keratosphere anchorage-independent growth. (A) HaCaT-derived 
keratospheres demonstrate anchorage-independent growth in the soft agar. 10 
000 cells of the parental HaCaT cells, dissociated keratospheres were seeded in 
the 6 wells in 4 replicates and propagated in two-layer agar-agarose system for 
30 days. Afterwards colonies were stained with crystal violet and photographed. 
Cervical carcinoma HeLa cells were added as positive control. HaCaT-MEGM 
represents HaCAT cells grown in soft agar experiment in keratosphere medium, 
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HaCaT-MEGM/MEGM – HaCaT cells, grown for 4 passages in tissue culture 
flasks in keratosphere medium, and put in soft agar experiment in the same 
medium (D) Dynamics of the tumorigenic phenotype acquisition by 
keratospheres:  soft agar assay performed with keratospheres at the different 
passages (p1, p8, p24, p54) reveled that keratospheres don’t acquire the ability 
to the anchorage-independent growth immediately but after some passages in 
the culture. 
 
Figure 5: Growth behavior of the keratospheres in vivo. (A) Tumor growth and 
survival curve in mice. 10
7
 of the HaCaT cells and dissociated keratospheres 
were injected subcutaneously into immunocompromised mice. The mice were 
monitored twice a week and tumor weight was calculated. As positive control 
A431 epidermoid carcinoma cells were added in the experiment and mice from 
this group in 6 days developed macroscopic SCCs and were sacrificed. HaCaT 
cells and keratospheres developed slow-growing neoplasms and it took 3 
months to obtain macroscopic tumors. (B-E) Histological analysis of the formed 
neoplasms. (B) Sample HaCaT, keratinizing cyst, 100X; (C) Sample HaCaT, 
keratinizing cyst, close up on keratohyalin granules, 200X; (D) Sample 
keratosphere: squamous cell carcinoma, 100X. (E) Sample keratosphere: 
epithelial pearl with keratohyalin granules, 200X. The pyogranuloma observed 
in this sample is a common finding in keratin-producing lesions where keratin is 
acts as a foreign body. 
 
Figure 6: Gene expression profiling of keratospheres. (A) Validation of the 
microarray HaCaT vs. tumour data by qPCR; (B) GO analysis for the up-
regulated genes retrieved epidermis development, keratinization, tissue 
development, epidermal cell differentiation with significant p-value and cell 
cycle process, mitotic cell cycle, cell division for the down-regulated genes; (C) 
Pathway analysis of microarray data revealed cell communication, Wnt and 
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Hedgehog signaling pathways upregulated and fatty acid metabolism, valine, 
leucine degradation, cell cycle downregulated upon tumorigenic conversion of 
the HaCaT keratinocytes to the keratospheres; (D) Global gene expression 
changes in parental HaCaT cells, keratospheres and tumor samples. Microarray 
data analysis demonstrate step-by step gene expression changes during transition 
from immortalized nontumorigenic HaCaT to the transformed keratospheres (at 
the passage 32) and following gene expression alterations upon SCC formation 
in the mice from .keratospheres. On the scheme the number of the overlapping 
genes for each stage is represented as well as appropriate GO categorization is 
present. 
 
Figure 7: p53 status and NF-YA isoforms in the different cell lines. To verify 
p53 status and presence of different NF-YA isoforms 30 µg of total extracts 
were analyzed by Western blot, using DO1 (α-p53) antibody (GeneSpin, Italy) 
and Mab1 (α-YA) antibody (homemade). In the Table below data about p53 
status, NF-YA isoforms and results of the overexpression experiment are 
summarized. 
 
Figure 8: Stable clones overexpressing different NF-YA isoforms and mutants 
of different isoforms. To obtain stable clones different cell lines were transduced 
with lentivitus, encoding NF-YA short and long isoforms and mutants of NF-
YA isoforms. Cells infected with lentivirus expressing empty vector served as a 
negative control. 48h post-transduction, we evaluated the efficiency of the 
infection by green fluorescence of the GFP-infected cells by fluorescent 
microscopy. 72h after infection cells were subjected to the puromycine selection 
and 1-2 weeks later cells were pooled, harvested and overexpression of the 
transgene was detected by Western blot. 
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Figure 9: Analysis of the growth characteristics of the stable clones. Growth 
rates of the stable clones overexpressing NF-YA were evaluated by MTT assay. 
 
Suppliment 1: Comparison of the microarray data (HaCaT vs. Tumour) revealed 
17 genes out of 25 (68%) intersecting with the genes of the list, comparing 
HNSCC versus normal mucosa (Yu et al., 2008).  
 
 
 
 
 
 
 
 
 
